
A leading provider of
innovative DNA Screening solutions
Ewing's sarcoma is the second most frequent primary bone cancer in patients below 20 years of age1. It is characterized mostly by translocation between the two genes EWSR1 (Ewing's Sarcoma Region 1) and FLI1 (Friend leukaemia virus integration 1) in the t(11;22)(q24;q12) translocation found in 85% of such tumours2. Ten percent of Ewing's sarcoma cases have a translocation involving EWSR1 and ERG (t(21;22) (q22;q12)) and less than 1% of Ewing's sarcoma patients harbour each of the 7p22 (ETV1), 17q12 (E1AF) and 2q36 (FEV) translocations with EWSR1. EWSR1 is also involved in translocations in desmoplasmic small round cell tumour, a subset of angiomatoid fibrous histocytomas and possibly in myxoid liposarcoma3,4. The EWSR1 breakapart probe can also be used to distinguish rare soft tissue sarcoma, a clear cell sarcoma from malignant myeloma which is hard to distinguish histologically and immunohistologically. EWS-ATF (Activating Transcription Factor) translocation t(12;22) (q13;q12) which never happens in the malignant myeloma, has been identified in 70% to over 90% of clear cell sarcoma5. FISH has been shown to be a more sensitive and reliable method than RT-PCR for the diagnosis of EWS in solid tissues6.
Cat. No. LPS 007
These products are only available labelled as Analyte Specific Reagents (ASR) in the USA.
Developed &